Abstract: A nanoparticle drug based on a small interfering RNA (siRNA) targeting JFK and use thereof are provided. Nucleotide sequences of the sense strand and the antisense strand of the siRNA targeting JFK are set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. Liposomes can be used to encapsulate the complex of the siRNA and a protamine to produce a nanoparticle drug targeting JFK, which may be used to treat a disease related to abnormally-high expression of JFK. In this disclosure, breast cancer 4T1 cell-based tumor-bearing mice serve as the model for evaluating the anti-tumor activity of combined therapy involving the nanoparticle drug targeting JFK and radiotherapy. The results reveal that this combined therapy exhibits superior anti-tumor activity compared to the control group.

Abstract: A fault-avoidance streamline calculation method for reservoir well pattern include: establishing a three-dimensional reservoir geological model using seismic and geological exploration data, and obtaining a grid-based reservoir model using triangulation technique; performing streamline simulation, and generating a streamline distribution of a reservoir well pattern in the grid-based reservoir model; determining a risk of contact between a streamline and a fault, and calculating an avoidance path; optimizing and adjusting well locations to ensure that the streamline and the fault do not intersect; and performing streamline verification. The method realizes efficient development of reservoirs.

Abstract: The present disclosure provides the utilization of an RPN11 marker in detecting myeloma and assessing disease risk, prognostic analysis, and therapeutic drug development. This includes a detection reagent and a kit for detecting smoldering multiple myeloma (SMM) and multiple myeloma (MM) and assessing disease risk. Additionally, it involves molecular typing of MM patients' cassette, prognostic analysis of the MM patients, and predicting the response of the MM patients to a bortezomib treatment. It entails the use of an RPN11 inhibitor in preparation of a pharmaceutical composition for treating MM characterized by drug-resistant t(4;14) translocation and a high RPN11 expression level. Notably, the combined use of the RPN11 with histone methyltransferase (HMT) enhances detection sensitivity and accuracy, preventing a mismatch between the patients' genotype and the prediction of disease development, and can effectively predict the overall survival and prognosis of MM patients with t(4;14) translocation.

Abstract: A nanoparticle drug based on a small interfering RNA (siRNA) targeting JFK and use thereof are provided. Nucleotide sequences of the sense strand and the antisense strand of the siRNA targeting JFK are set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. Liposomes can be used to encapsulate the complex of the siRNA and a protamine to produce a nanoparticle drug targeting JFK, which may be used to treat a disease related to abnormally-high expression of JFK. In this disclosure, breast cancer 4T1 cell-based tumor-bearing mice serve as the model for evaluating the anti-tumor activity of combined therapy involving the nanoparticle drug targeting JFK and radiotherapy. The results reveal that this combined therapy exhibits superior anti-tumor activity compared to the control group.